{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:16:04Z","timestamp":1794287764545,"version":"4.9.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that is highly pathogenic and has caused the recent worldwide pandemic officially named coronavirus disease (COVID-19). Currently, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Vaccines, such as inactivated vaccines, nucleic acid-based vaccines, and vector vaccines, have already entered clinical trials. In this review, we provide an overview of the experimental and clinical data obtained from recent SARS-CoV-2 vaccines trials, and highlight certain potential safety issues that require consideration when developing vaccines. Furthermore, we summarize several strategies utilized in the development of vaccines against other infectious viruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), with the aim of aiding in the design of effective therapeutic approaches against SARS-CoV-2.<\/jats:p>","DOI":"10.1038\/s41392-020-00352-y","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T11:03:31Z","timestamp":1602587011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":438,"title":["A systematic review of SARS-CoV-2 vaccine candidates"],"prefix":"10.1038","volume":"5","author":[{"given":"Yetian","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-0474","authenticated-orcid":false,"given":"Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"352_CR1","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/all.14238","volume":"75","author":"JJ Zhang","year":"2020","unstructured":"Zhang, J. J. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 75, 1730\u20131741 (2020).","journal-title":"Allergy"},{"key":"352_CR2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama 323, 1061\u20131069 (2020).","journal-title":"Jama"},{"key":"352_CR3","doi-asserted-by":"publisher","unstructured":"Wang, M. et al. Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan. medRxiv, https:\/\/doi.org\/10.1101\/2020.02.12.20022327 (2020).","DOI":"10.1101\/2020.02.12.20022327"},{"key":"352_CR4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama 323, 1239\u20131242 (2020).","journal-title":"Jama"},{"key":"352_CR5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","volume":"27","author":"A Wu","year":"2020","unstructured":"Wu, A. et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 27, 325\u2013328 (2020).","journal-title":"Cell Host Microbe."},{"key":"352_CR6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507\u2013513 (2020).","journal-title":"Lancet"},{"key":"352_CR7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41591-020-0771-1","volume":"26","author":"J Nkengasong","year":"2020","unstructured":"Nkengasong, J. China\u2019s response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response. Nat. Med. 26, 310\u2013311 (2020).","journal-title":"Nat. Med."},{"key":"352_CR8","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"352_CR9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","volume":"368","author":"W Dai","year":"2020","unstructured":"Dai, W. et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368, 1331\u20131335 (2020).","journal-title":"Science"},{"key":"352_CR10","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","volume":"368","author":"W Yin","year":"2020","unstructured":"Yin, W. et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 368, 1499\u20131504 (2020).","journal-title":"Science"},{"key":"352_CR11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","volume":"92","author":"Y Chen","year":"2020","unstructured":"Chen, Y., Liu, Q. & Guo, D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J. Med. Virol. 92, 418\u2013423 (2020).","journal-title":"J. Med. Virol."},{"key":"352_CR12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","volume":"20","author":"KK To","year":"2020","unstructured":"To, K. K. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 20, 565\u2013574 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"352_CR13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"352_CR14","volume":"11","author":"X Ou","year":"2020","unstructured":"Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020).","journal-title":"Nat. Commun."},{"key":"352_CR15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"352_CR16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562\u2013569 (2020).","journal-title":"Nat. Microbiol."},{"key":"352_CR17","first-page":"e00127","volume":"94","author":"Y Wan","year":"2020","unstructured":"Wan, Y. et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 94, e00127\u201320 (2020).","journal-title":"J. Virol."},{"key":"352_CR18","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abd4251","volume":"369","author":"Y Cai","year":"2020","unstructured":"Cai, Y. et al. Distinct conformational states of SARS-CoV-2 spike protein. Science 369, 1586\u20131592 (2020).","journal-title":"Science"},{"key":"352_CR19","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1073\/pnas.0401939101","volume":"101","author":"H Bisht","year":"2004","unstructured":"Bisht, H. et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl Acad. Sci. USA 101, 6641\u20136646 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"352_CR20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature02463","volume":"428","author":"Z-y Yang","year":"2004","unstructured":"Yang, Z.-y et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561\u2013564 (2004).","journal-title":"Nature"},{"key":"352_CR21","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","volume":"26","author":"JE Martin","year":"2008","unstructured":"Martin, J. E. et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 26, 6338\u20136343 (2008).","journal-title":"Vaccine"},{"key":"352_CR22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","volume":"52","author":"F Amanat","year":"2020","unstructured":"Amanat, F. & Krammer, F. SARS-CoV-2 vaccines: status report. Immunity 52, 583\u2013589 (2020).","journal-title":"Immunity"},{"key":"352_CR23","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ebiom.2015.08.031","volume":"2","author":"J Lan","year":"2015","unstructured":"Lan, J. et al. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine 2, 1438\u20131446 (2015).","journal-title":"EBioMedicine"},{"key":"352_CR24","volume":"7","author":"J Wang","year":"2012","unstructured":"Wang, J. et al. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PLoS ONE 7, e37019 (2012).","journal-title":"PLoS ONE"},{"key":"352_CR25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbrc.2004.10.052","volume":"325","author":"Y He","year":"2004","unstructured":"He, Y., Zhou, Y., Siddiqui, P. & Jiang, S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem. Biophys. Res. Commun. 325, 445\u2013452 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"352_CR26","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.xcrm.2020.100040","volume":"1","author":"MS Suthar","year":"2020","unstructured":"Suthar, M. S. et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep. Med. 1, 100040 (2020).","journal-title":"Cell Rep. Med."},{"key":"352_CR27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77\u201381 (2020).","journal-title":"Science"},{"key":"352_CR28","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","volume":"53","author":"L Ni","year":"2020","unstructured":"Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 53, 971\u2013977.e3 (2020).","journal-title":"Immunity"},{"key":"352_CR29","doi-asserted-by":"publisher","unstructured":"Quinlan, B. D. et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. bioRxiv, https:\/\/doi.org\/10.1101\/2020.04.10.036418 (2020).","DOI":"10.1101\/2020.04.10.036418"},{"key":"352_CR30","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036\u20131045.e9 (2020).","journal-title":"Cell"},{"key":"352_CR31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718\u2013724 (2020).","journal-title":"Science"},{"key":"352_CR32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459\u2013468 (2020).","journal-title":"Nature"},{"key":"352_CR33","doi-asserted-by":"publisher","unstructured":"Zhang, Y. et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through potently downregulating MHC-I. bioRxiv, https:\/\/doi.org\/10.1101\/2020.05.24.111823 (2020).","DOI":"10.1101\/2020.05.24.111823"},{"key":"352_CR34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.imlet.2004.01.001","volume":"92","author":"MS Zhu","year":"2004","unstructured":"Zhu, M. S. et al. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol. Lett. 92, 237\u2013243 (2004).","journal-title":"Immunol. Lett."},{"key":"352_CR35","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(03)14962-8","volume":"362","author":"W Gao","year":"2003","unstructured":"Gao, W. et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362, 1895\u20131896 (2003).","journal-title":"Lancet"},{"key":"352_CR36","first-page":"193","volume":"1","author":"M Zhu","year":"2004","unstructured":"Zhu, M. SARS immunity and vaccination. Cell Mol. Immunol. 1, 193\u2013198 (2004).","journal-title":"Cell Mol. Immunol."},{"key":"352_CR37","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1128\/JVI.78.9.4638-4645.2004","volume":"78","author":"TW Kim","year":"2004","unstructured":"Kim, T. W. et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J. Virol. 78, 4638\u20134645 (2004).","journal-title":"J. Virol."},{"key":"352_CR38","doi-asserted-by":"crossref","unstructured":"Gralinski, L. E. & Menachery, V. D. Return of the coronavirus: 2019-nCoV. Viruses 12, 135 (2020).","DOI":"10.3390\/v12020135"},{"key":"352_CR39","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1099\/vir.0.80111-0","volume":"85","author":"H Pang","year":"2004","unstructured":"Pang, H. et al. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J. Gen. Virol. 85, 3109\u20133113 (2004).","journal-title":"J. Gen. Virol."},{"key":"352_CR40","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e15 (2020).","journal-title":"Cell"},{"key":"352_CR41","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1586\/erv.09.43","volume":"8","author":"RL Roper","year":"2009","unstructured":"Roper, R. L. & Rehm, K. E. SARS vaccines: where are we? Expert Rev. Vaccines 8, 887\u2013898 (2009).","journal-title":"Expert Rev. Vaccines"},{"key":"352_CR42","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","volume":"182","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182, 713\u2013721.e9 (2020).","journal-title":"Cell"},{"key":"352_CR43","doi-asserted-by":"publisher","unstructured":"Zhang, Y.-J. et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial. medRxiv, https:\/\/doi.org\/10.1101\/2020.07.31.20161216 (2020).","DOI":"10.1101\/2020.07.31.20161216"},{"key":"352_CR44","doi-asserted-by":"publisher","unstructured":"Xia, S. et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama, https:\/\/doi.org\/10.1001\/jama.2020.15543 (2020).","DOI":"10.1001\/jama.2020.15543"},{"key":"352_CR45","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","volume":"479-480","author":"PD Minor","year":"2015","unstructured":"Minor, P. D. Live attenuated vaccines: historical successes and current challenges. Virology 479-480, 379\u2013392 (2015).","journal-title":"Virology"},{"key":"352_CR46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines\u2014a new era in vaccinology. Nat. Rev. Drug Disco. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Disco."},{"key":"352_CR47","volume":"26","author":"F Wang","year":"2020","unstructured":"Wang, F., Kream, R. M. & Stefano, G. B. An evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Med Sci. Monit. 26, e924700 (2020).","journal-title":"Med Sci. Monit."},{"key":"352_CR48","doi-asserted-by":"publisher","unstructured":"Mulligan, M. J. et al. Phase 1\/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, https:\/\/doi.org\/10.1038\/s41586-020-2639-4 (2020).","DOI":"10.1038\/s41586-020-2639-4"},{"key":"352_CR49","doi-asserted-by":"publisher","unstructured":"Jackson, L. A. et al. An mRNA Vaccine against SARS-CoV-2\u2014preliminary report. N. Eng. J. Med., https:\/\/doi.org\/10.1056\/NEJMoa2022483 (2020).","DOI":"10.1056\/NEJMoa2022483"},{"key":"352_CR50","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","volume":"182","author":"NN Zhang","year":"2020","unstructured":"Zhang, N. N. et al. A Thermostable mRNA Vaccine against COVID-19. Cell 182, 1271\u20131283.e16 (2020).","journal-title":"Cell"},{"key":"352_CR51","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.3390\/ijms19113605","volume":"19","author":"D Hobernik","year":"2018","unstructured":"Hobernik, D. & Bros, M. DNA Vaccines-How far from clinical use? Int. J. Mol. Sci. 19, 3605 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"352_CR52","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811 (2020).","journal-title":"Science"},{"key":"352_CR53","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","volume":"19","author":"K Modjarrad","year":"2019","unstructured":"Modjarrad, K. et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect. Dis. 19, 1013\u20131022 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"352_CR54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/cei.13295","volume":"196","author":"B Afrough","year":"2019","unstructured":"Afrough, B., Dowall, S. & Hewson, R. Emerging viruses and current strategies for vaccine intervention. Clin. Exp. Immunol. 196, 157\u2013166 (2019).","journal-title":"Clin. Exp. Immunol."},{"key":"352_CR55","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","volume":"396","author":"F-C Zhu","year":"2020","unstructured":"Zhu, F.-C. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396, 479\u2013488 (2020).","journal-title":"Lancet"},{"key":"352_CR56","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu, F. C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845\u20131854 (2020).","journal-title":"Lancet"},{"key":"352_CR57","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"DY Logunov","year":"2020","unstructured":"Logunov, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet 396, 887\u2013897 (2020).","journal-title":"Lancet"},{"key":"352_CR58","doi-asserted-by":"publisher","unstructured":"van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, https:\/\/doi.org\/10.1038\/s41586-020-2608-y (2020).","DOI":"10.1038\/s41586-020-2608-y"},{"key":"352_CR59","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"352_CR60","doi-asserted-by":"publisher","unstructured":"Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, https:\/\/doi.org\/10.1038\/s41586-020-2607-z (2020).","DOI":"10.1038\/s41586-020-2607-z"},{"key":"352_CR61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/bs.aivir.2016.08.003","volume":"96","author":"L Enjuanes","year":"2016","unstructured":"Enjuanes, L. et al. Molecular basis of coronavirus virulence and vaccine development. Adv. Virus Res 96, 245\u2013286 (2016).","journal-title":"Adv. Virus Res"},{"key":"352_CR62","doi-asserted-by":"publisher","unstructured":"Yang, J. et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature, https:\/\/doi.org\/10.1038\/s41586-020-2599-8 (2020).","DOI":"10.1038\/s41586-020-2599-8"},{"key":"352_CR63","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbt.2017.07.010","volume":"39","author":"J Fuenmayor","year":"2017","unstructured":"Fuenmayor, J., G\u00f2dia, F. & Cervera, L. Production of virus-like particles for vaccines. N. Biotechnol. 39, 174\u2013180 (2017).","journal-title":"N. Biotechnol."},{"key":"352_CR64","doi-asserted-by":"crossref","first-page":"107725","DOI":"10.1016\/j.celrep.2020.107725","volume":"31","author":"H Lv","year":"2020","unstructured":"Lv, H. et al. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep. 31, 107725 (2020).","journal-title":"Cell Rep."},{"key":"352_CR65","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","volume":"382","author":"N Lurie","year":"2020","unstructured":"Lurie, N., Saville, M., Hatchett, R. & Halton, J. Developing Covid-19 vaccines at pandemic speed. N. Engl. J. Med. 382, 1969\u20131973 (2020).","journal-title":"N. Engl. J. Med."},{"key":"352_CR66","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1126\/science.abc7424","volume":"369","author":"AZ Wec","year":"2020","unstructured":"Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369, 731\u2013736 (2020).","journal-title":"Science"},{"key":"352_CR67","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","volume":"369","author":"TF Rogers","year":"2020","unstructured":"Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956\u2013963 (2020).","journal-title":"Science"},{"key":"352_CR68","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells. Cell 182, 73\u201384.e16 (2020).","journal-title":"Cell"},{"key":"352_CR69","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","volume":"368","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274\u20131278 (2020).","journal-title":"Science"},{"key":"352_CR70","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120\u2013124 (2020).","journal-title":"Nature"},{"key":"352_CR71","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115\u2013119 (2020).","journal-title":"Nature"},{"key":"352_CR72","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41423-020-0426-7","volume":"17","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol. Immunol. 17, 647\u2013649 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"352_CR73","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643\u2013650 (2020).","journal-title":"Science"},{"key":"352_CR74","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.immuni.2020.06.001","volume":"53","author":"E Seydoux","year":"2020","unstructured":"Seydoux, E. et al. Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity 53, 98\u2013105.e5 (2020).","journal-title":"Immunity"},{"key":"352_CR75","volume":"11","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 11, 2251 (2020).","journal-title":"Nat. Commun."},{"key":"352_CR76","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"352_CR77","doi-asserted-by":"crossref","unstructured":"Burton, D. R. What are the most powerful immunogen design vaccine strategies? Reverse vaccinology 2.0 shows great promise. Cold Spring Harb. Perspect. Biol. 9, a030262 (2017).","DOI":"10.1101\/cshperspect.a030262"},{"key":"352_CR78","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3389\/fimmu.2017.01802","volume":"8","author":"Y Wu","year":"2017","unstructured":"Wu, Y., Jiang, S. & Ying, T. Single-Domain Antibodies As Therapeutics against Human Viral Diseases. Front Immunol. 8, 1802 (2017).","journal-title":"Front Immunol."},{"key":"352_CR79","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1517\/17425247.2015.999039","volume":"12","author":"R Respaud","year":"2015","unstructured":"Respaud, R., Vecellio, L., Diot, P. & Heuz\u00e9-Vourc\u2019h, N. Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin. Drug Deliv. 12, 1027\u20131039 (2015).","journal-title":"Expert Opin. Drug Deliv."},{"key":"352_CR80","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.ddtec.2010.03.002","volume":"7","author":"JA Kolkman","year":"2010","unstructured":"Kolkman, J. A. & Law, D. A. Nanobodies\u2013from llamas to therapeutic proteins. Drug Discov. Today.: Technol. 7, e139\u2013e146 (2010).","journal-title":"Drug Discov. Today.: Technol."},{"key":"352_CR81","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","volume":"181","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell 181, 1004\u20131015.e15 (2020).","journal-title":"Cell"},{"key":"352_CR82","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.chom.2020.04.023","volume":"27","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. Identification of human single-domain antibodies against SARS-CoV-2. Cell Host Microbe 27, 891\u2013898.e5 (2020).","journal-title":"Cell Host Microbe"},{"key":"352_CR83","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1073\/pnas.0307140101","volume":"101","author":"J Sui","year":"2004","unstructured":"Sui, J. et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl Acad. Sci. USA 101, 2536\u20132541 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"352_CR84","doi-asserted-by":"publisher","unstructured":"Yuan, A. Q. et al. Isolation of and characterization of neutralizing antibodies to Covid-19 from a large human na\u00efve scFv phage display library. bioRxiv, https:\/\/doi.org\/10.1101\/2020.05.19.104281 (2020).","DOI":"10.1101\/2020.05.19.104281"},{"key":"352_CR85","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9223","volume":"6","author":"T Ying","year":"2015","unstructured":"Ying, T. et al. Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat. Commun. 6, 8223 (2015).","journal-title":"Nat. Commun."},{"key":"352_CR86","volume":"5","author":"X Yu","year":"2015","unstructured":"Yu, X. et al. Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27. Sci. Rep. 5, 13133 (2015).","journal-title":"Sci. Rep."},{"key":"352_CR87","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bios.2006.01.010","volume":"22","author":"S Townsend","year":"2006","unstructured":"Townsend, S., Finlay, W. J., Hearty, S. & O\u2019Kennedy, R. Optimizing recombinant antibody function in SPR immunosensing. The influence of antibody structural format and chip surface chemistry on assay sensitivity. Biosens. Bioelectron. 22, 268\u2013274 (2006).","journal-title":"Biosens. Bioelectron."},{"key":"352_CR88","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827.e19 (2020).","journal-title":"Cell"},{"key":"352_CR89","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","volume":"369","author":"A Baum","year":"2020","unstructured":"Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014\u20131018 (2020).","journal-title":"Science"},{"key":"352_CR90","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010\u20131014 (2020).","journal-title":"Science"},{"key":"352_CR91","doi-asserted-by":"crossref","first-page":"107918","DOI":"10.1016\/j.celrep.2020.107918","volume":"32","author":"J Wan","year":"2020","unstructured":"Wan, J. et al. Human-IgG-neutralizing monoclonal antibodies block the SARS-CoV-2 infection. Cell Rep. 32, 107918 (2020).","journal-title":"Cell Rep."},{"key":"352_CR92","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","volume":"7","author":"CT Tseng","year":"2012","unstructured":"Tseng, C. T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7, e35421 (2012).","journal-title":"PLoS ONE"},{"key":"352_CR93","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","volume":"12","author":"AS Agrawal","year":"2016","unstructured":"Agrawal, A. S. et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum. Vaccin Immunother. 12, 2351\u20132356 (2016).","journal-title":"Hum. Vaccin Immunother."},{"key":"352_CR94","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","volume":"181","author":"F Yasui","year":"2008","unstructured":"Yasui, F. et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J. Immunol. 181, 6337\u20136348 (2008).","journal-title":"J. Immunol."},{"key":"352_CR95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030525","volume":"3","author":"D Deming","year":"2006","unstructured":"Deming, D. et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 3, e525 (2006).","journal-title":"PLoS Med."},{"key":"352_CR96","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.16659","volume":"189","author":"S Wan","year":"2020","unstructured":"Wan, S. et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br. J. Haematol. 189, 428\u2013437 (2020).","journal-title":"Br. J. Haematol."},{"key":"352_CR97","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"352_CR98","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/nsr\/nwaa041","volume":"7","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl. Sci. Rev. 7, 998\u20131002 (2020).","journal-title":"Natl. Sci. Rev"},{"key":"352_CR99","volume":"4","author":"L Liu","year":"2019","unstructured":"Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, e123158 (2019).","journal-title":"JCI Insight"},{"key":"352_CR100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.20499","volume":"78","author":"L Zhang","year":"2006","unstructured":"Zhang, L. et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J. Med Virol. 78, 1\u20138 (2006).","journal-title":"J. Med Virol."},{"key":"352_CR101","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fmolb.2020.00157","volume":"7","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19. Front Mol. Biosci. 7, 157 (2020).","journal-title":"Front Mol. Biosci."},{"key":"352_CR102","doi-asserted-by":"publisher","unstructured":"Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis., https:\/\/doi.org\/10.1093\/cid\/ciaa344 (2020).","DOI":"10.1093\/cid\/ciaa344"},{"key":"352_CR103","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","volume":"85","author":"M Bolles","year":"2011","unstructured":"Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201\u201312215 (2011).","journal-title":"J. Virol."},{"key":"352_CR104","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/jmv.25722","volume":"92","author":"P Sun","year":"2020","unstructured":"Sun, P. et al. Understanding of COVID-19 based on current evidence. J. Med Virol. 92, 548\u2013551 (2020).","journal-title":"J. Med Virol."},{"key":"352_CR105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565\u2013574 (2020).","journal-title":"Lancet"},{"key":"352_CR106","doi-asserted-by":"crossref","unstructured":"Ahmed, S. F., Quadeer, A. A. & McKay, M. R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12, 254 (2020).","DOI":"10.3390\/v12030254"},{"key":"352_CR107","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","volume":"27","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe 27, 671\u2013680.e2 (2020).","journal-title":"Cell Host Microbe"},{"key":"352_CR108","doi-asserted-by":"crossref","unstructured":"Mukherjee, S. et al. Immunoinformatics and structural analysis for identification of immunodominant epitopes in SARS-CoV-2 as potential vaccine targets. Vaccines 8, 290 (2020).","DOI":"10.3390\/vaccines8020290"},{"key":"352_CR109","doi-asserted-by":"publisher","unstructured":"Ramaiah, A. & Arumugaswami, V. Insights into cross-species evolution of novel human coronavirus 2019-nCoV and defining immune determinants for vaccine development. bioRxiv, https:\/\/doi.org\/10.1101\/2020.01.29.925867 (2020).","DOI":"10.1101\/2020.01.29.925867"},{"key":"352_CR110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","volume":"2","author":"Q Wang","year":"2016","unstructured":"Wang, Q. et al. Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect. Dis. 2, 361\u2013376 (2016).","journal-title":"ACS Infect. Dis."},{"key":"352_CR111","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"352_CR112","doi-asserted-by":"crossref","first-page":"100036","DOI":"10.1016\/j.xcrm.2020.100036","volume":"1","author":"M Yarmarkovich","year":"2020","unstructured":"Yarmarkovich, M., Warrington, J. M., Farrel, A. & Maris, J. M. Identification of SARS-CoV-2 vaccine epitopes predicted to induce long-term population-scale immunity. Cell Rep. Med. 1, 100036 (2020).","journal-title":"Cell Rep. Med."},{"key":"352_CR113","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"396","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 396, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"352_CR114","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"L Dai","year":"2020","unstructured":"Dai, L. et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 182, 722\u2013733.e11 (2020).","journal-title":"Cell"},{"key":"352_CR115","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1016\/j.vaccine.2007.05.025","volume":"25","author":"YK Cheung","year":"2007","unstructured":"Cheung, Y. K. et al. Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope. Vaccine 25, 6070\u20136077 (2007).","journal-title":"Vaccine"},{"key":"352_CR116","doi-asserted-by":"crossref","unstructured":"Zhang, J. et al. Progress and prospects on vaccine development against SARS-CoV-2. Vaccines 8, 153 (2020).","DOI":"10.3390\/vaccines8020153"},{"key":"352_CR117","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","volume":"89","author":"Y Honda-Okubo","year":"2015","unstructured":"Honda-Okubo, Y. et al. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J. Virol. 89, 2995\u20133007 (2015).","journal-title":"J. Virol."},{"key":"352_CR118","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.0818-9641.2004.01286.x","volume":"82","author":"EB Lindblad","year":"2004","unstructured":"Lindblad, E. B. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 82, 497\u2013505 (2004).","journal-title":"Immunol. Cell Biol."},{"key":"352_CR119","doi-asserted-by":"crossref","DOI":"10.1038\/s41426-018-0056-7","volume":"7","author":"Y Deng","year":"2018","unstructured":"Deng, Y. et al. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg. Microbes Infect. 7, 60 (2018).","journal-title":"Emerg. Microbes Infect."},{"key":"352_CR120","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4049\/jimmunol.160.2.870","volume":"160","author":"HL Davis","year":"1998","unstructured":"Davis, H. L. et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870\u2013876 (1998).","journal-title":"J. Immunol."},{"key":"352_CR121","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/vim.2010.0028","volume":"23","author":"A Roberts","year":"2010","unstructured":"Roberts, A. et al. Immunogenicity and protective efficacy in mice and hamsters of a \u03b2-propiolactone inactivated whole virus SARS-CoV vaccine. Viral Immunol. 23, 509\u2013519 (2010).","journal-title":"Viral Immunol."},{"key":"352_CR122","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1126\/science.1089926","volume":"304","author":"MB Jordan","year":"2004","unstructured":"Jordan, M. B. et al. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304, 1808\u20131810 (2004).","journal-title":"Science"},{"key":"352_CR123","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/cmi.2015.03","volume":"13","author":"N Zhang","year":"2016","unstructured":"Zhang, N. et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol. Immunol. 13, 180\u2013190 (2016).","journal-title":"Cell Mol. Immunol."},{"key":"352_CR124","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1128\/JVI.00983-14","volume":"88","author":"N Iwata-Yoshikawa","year":"2014","unstructured":"Iwata-Yoshikawa, N. et al. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB\/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J. Virol. 88, 8597\u20138614 (2014).","journal-title":"J. Virol."},{"key":"352_CR125","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/jac\/dkr588","volume":"67","author":"NJ Horscroft","year":"2012","unstructured":"Horscroft, N. J., Pryde, D. C. & Bright, H. Antiviral applications of Toll-like receptor agonists. J. Antimicrob. Chemother. 67, 789\u2013801 (2012).","journal-title":"J. Antimicrob. Chemother."},{"key":"352_CR126","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1128\/JVI.76.13.6652-6659.2002","volume":"76","author":"S Sasaki","year":"2002","unstructured":"Sasaki, S. et al. Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J. Virol. 76, 6652\u20136659 (2002).","journal-title":"J. Virol."},{"key":"352_CR127","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.vetimm.2010.04.008","volume":"137","author":"C Wan","year":"2010","unstructured":"Wan, C. et al. The Toll-like receptor adaptor molecule TRIF enhances DNA vaccination against classical swine fever. Vet. Immunol. Immunopathol. 137, 47\u201353 (2010).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"352_CR128","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.vaccine.2011.01.060","volume":"29","author":"M Luo","year":"2011","unstructured":"Luo, M. et al. The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice. Vaccine 29, 2561\u20132567 (2011).","journal-title":"Vaccine"},{"key":"352_CR129","doi-asserted-by":"crossref","first-page":"15107","DOI":"10.1128\/JVI.79.24.15107-15113.2005","volume":"79","author":"JH Aberle","year":"2005","unstructured":"Aberle, J. H., Aberle, S. W., Kofler, R. M. & Mandl, C. W. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus. J. Virol. 79, 15107\u201315113 (2005).","journal-title":"J. Virol."},{"key":"352_CR130","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1084\/jem.188.6.1075","volume":"188","author":"A Porgador","year":"1998","unstructured":"Porgador, A. et al. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med. 188, 1075\u20131082 (1998).","journal-title":"J. Exp. Med."},{"key":"352_CR131","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.4049\/jimmunol.164.9.4635","volume":"164","author":"G Widera","year":"2000","unstructured":"Widera, G. et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 164, 4635\u20134640 (2000).","journal-title":"J. Immunol."},{"key":"352_CR132","volume":"7","author":"DX Johansson","year":"2012","unstructured":"Johansson, D. X., Ljungberg, K., Kakoulidou, M. & Liljestr\u00f6m, P. Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS ONE 7, e29732 (2012).","journal-title":"PLoS ONE"},{"key":"352_CR133","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1128\/JVI.01049-10","volume":"84","author":"J Zhao","year":"2010","unstructured":"Zhao, J., Zhao, J. & Perlman, S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J. Virol. 84, 9318\u20139325 (2010).","journal-title":"J. Virol."},{"key":"352_CR134","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/jvh.12542","volume":"23","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. Enhanced immunity and antiviral effects of an HBV DNA vaccine delivered by a DC-targeting protein. J. Viral Hepat. 23, 798\u2013804 (2016).","journal-title":"J. Viral Hepat."},{"key":"352_CR135","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.bbrc.2015.03.015","volume":"460","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. Design, expression, and characterization of a novel dendritic cell-targeted proteins. Biochem Biophys. Res. Commun. 460, 227\u2013232 (2015).","journal-title":"Biochem Biophys. Res. Commun."},{"key":"352_CR136","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","volume":"109","author":"AJ Geall","year":"2012","unstructured":"Geall, A. J. et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl Acad. Sci. USA 109, 14604\u201314609 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"352_CR137","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.vaccine.2015.10.132","volume":"34","author":"G Swaminathan","year":"2016","unstructured":"Swaminathan, G. et al. A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens. Vaccine 34, 110\u2013119 (2016).","journal-title":"Vaccine"},{"key":"352_CR138","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao, B. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382, 1787\u20131799 (2020).","journal-title":"N. Engl. J. Med."},{"key":"352_CR139","volume":"3","author":"MGS Borba","year":"2020","unstructured":"Borba, M. G. S. et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw. Open 3, e208857 (2020).","journal-title":"JAMA Netw. Open"},{"key":"352_CR140","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41591-020-0888-2","volume":"26","author":"E Chorin","year":"2020","unstructured":"Chorin, E. et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat. Med. 26, 808\u2013809 (2020).","journal-title":"Nat. Med."},{"key":"352_CR141","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"P Gautret","year":"2020","unstructured":"Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J. Antimicrob. Agents 56, 105949 (2020).","journal-title":"Int J. Antimicrob. Agents"},{"key":"352_CR142","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","volume":"28","author":"SH Sun","year":"2020","unstructured":"Sun, S. H. et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28, 124\u2013133.e4 (2020).","journal-title":"Cell Host Microbe"},{"key":"352_CR143","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","volume":"182","author":"RD Jiang","year":"2020","unstructured":"Jiang, R. D. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 50\u201358.e8 (2020).","journal-title":"Cell"},{"key":"352_CR144","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1126\/science.abc4776","volume":"369","author":"A Chandrashekar","year":"2020","unstructured":"Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369, 812\u2013817 (2020).","journal-title":"Science"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-00352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-00352-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-00352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T17:00:31Z","timestamp":1696870831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-00352-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["352"],"URL":"https:\/\/doi.org\/10.1038\/s41392-020-00352-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]},"assertion":[{"value":"10 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}